These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28590785)

  • 1. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
    Weir MR; Berger JS; Ashton V; Laliberté F; Brown K; Lefebvre P; Schein J
    Curr Med Res Opin; 2017 Oct; 33(10):1891-1900. PubMed ID: 28590785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.
    Weir MR; Haskell L; Berger JS; Ashton V; Laliberté F; Crivera C; Brown K; Lefebvre P; Schein J
    Clin Nephrol; 2018 May; 89(5):314-329. PubMed ID: 29231162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
    Simon TG; Singer DE; Zhang Y; Mastrorilli JM; Cervone A; DiCesare E; Lin KJ
    Ann Intern Med; 2024 Aug; 177(8):1028-1038. PubMed ID: 38976880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
    Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
    Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
    Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.
    Alberts M; Chen YW; Lin JH; Kogan E; Twyman K; Milentijevic D
    Stroke; 2020 Feb; 51(2):549-555. PubMed ID: 31888412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    J Diabetes Complications; 2021 Nov; 35(11):108029. PubMed ID: 34538715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
    Coleman CI; Thompson S; Ashton V; Palladino M; Bunz TJ
    J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
    Weir MR; Ashton V; Moore KT; Shrivastava S; Peterson ED; Ammann EM
    Am Heart J; 2020 May; 223():3-11. PubMed ID: 32112872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.
    Alberts MJ; He J; Kharat A; Ashton V
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):425-436. PubMed ID: 35092000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
    Milentijevic D; Lin JH; Connolly N; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts MJ
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105715. PubMed ID: 33743312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
    Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
    Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
    Adv Ther; 2021 Jul; 38(7):3771-3788. PubMed ID: 34031859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis.
    Coleman CI; Kreutz R; Sood N; Bunz TJ; Meinecke AK; Eriksson D; Baker WL
    Clin Appl Thromb Hemost; 2019; 25():1076029619868535. PubMed ID: 31392894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.